A Multiple Dose Clinical Trial to Study the Safety, Tolerability, Pharmacokinetics and Pharmacodynamics of MK-1006
Phase of Trial: Phase I
Latest Information Update: 24 Dec 2014
At a glance
- Drugs MK 1006 (Primary)
- Indications Type 2 diabetes mellitus
- Focus Adverse reactions
- Sponsors Merck Sharp & Dohme
- 17 Dec 2009 Planned end date changed from 1 Sep 2010 to 1 Oct 2010 as reported by ClinicalTrials.gov.
- 08 Apr 2009 Status changed from recruiting to active, no longer recruiting as reported by ClinicalTrials.gov.
- 10 Oct 2008 New trial record.